The "KEY OF HOPE" program is aimed at increasing the awareness of patients about the disease and reducing the cost of therapy for the patient with drugs included in the Program, intended for the treatment of certain types of oncological diseases by influencing the immune system;
Preparation of the project:
KITRUDA® (pembrolizumab)
Keytruda conc. d/r-nu d/inf. 25 mg/ml fl. 4 ml No. 1
The promotion is held until: 31.12.2025
You can learn more about the terms of participation in the project on the website: https://medicard.com.ua/medicard/page/key_hope_ruless/
The "Asakard" program was developed by the Biocodex company in order to ease your burden during the long-term treatment of intestinal diseases.
Drugs:
ASAKOL® coated tablets, enteric-soluble 800 mg No. 60;
ASAKOL® coated tablets, enteric-soluble 400 mg No. 100;
ASAKOL® rectal suppositories of 500 mg No. 20.You can learn more about the terms of participation in the project on the website:https://privit.com.ua/asacard/
the company is focused on the key needs in healthcare, the development of new medicines, technologies and treatments. This is an international diversified company operating in the health sector. Time-tested products are highly appreciated by experts worldwide for its efficiency, reliability and safety. Program Time (ABBOTT CARDS ) provides the opportunity to purchase efficient medications at a more affordable price.
Drugs project:
Heptral since.lyophil.d/R-RA d/INF.500mg FL., No. The 5+solution.amp.5ml No. 5
Heptral tab.enteric solution.500 mg No. 20More details about conditions of participation in the project can be found on the project website Abbott cards
Darnitsa is a pharmaceutical company, a leader in Ukrainian market in the production and physical sales of prescription (Rx) and over-the-counter (OTC) generic products. The company began operating in 1930. In 2019, Darnitsa rebranded and announced a new business strategy: to transform based on digital technologies, to build an international brand and to lead in the generic segment of medicines.
The company's portfolio includes 280 names of ready-to-use drugs. Darnitsa focuses on the treatment of cardiac, neurological diseases and pain. Its products are exported to 16 countries.
The Darnitsa plant in Kyiv has 14 production lines certified according to the GMP standard.
Farmak is the leader of pharmaceutical market with a share of 5.9 %. The medicines of all fourteen therapeutic groups are produced at the factory. Among the main areas are anti-cold, endocrinological, gastroenterological, cardiological and neurological portfolios. Every year, Farmak launches approximately 20 new drugs on the market; these are complex modern medications needed by millions of people, both in our country and abroad. About a hundred drugs are currently under development.
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, respiratory diseases.
Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organization covers almost all key European markets and a few Southeast Asian countries. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.
“PLUS Therapy” – the program aims to support patients with chronic diseases in areas such as cardiology, endocrinology, pneumology, psychiatry and Oncology. For each Drug, which participates in the Program, define an appropriate charging scheme discounts. The discount is given to cardholders ‘Terapias”, which are issued to patients who had been prescribed the drug involved in the Program “Terapias”, by a doctor of the healthcare institution.
Drugs project:
Ось переклад англійською мовою:
Brilinta film-coated tablets 90 mg No. 56
Brilinta film-coated tablets 60 mg No. 56
Kombiglyze XR film-coated tablets 5 mg / 1000 mg No. 28
Crestor film-coated tablets 10 mg No. 28
Crestor film-coated tablets 20 mg No. 28
Crestor film-coated tablets 40 mg No. 28
Crestor film-coated tablets 5 mg No. 28
Onglyza film-coated tablets 5 mg No. 30
Xigduo XR prolonged-release film-coated tablets 10 mg / 1000 mg No. 28
Xigduo XR prolonged-release film-coated tablets 5 mg / 1000 mg No. 28
Trixeo Aerosphere pressurized inhalation suspension 5 / 7.2 / 160 mcg, 120-dose canister No. 1
More details about conditions of participation in the project can be found on the project website Therapy PLUS
«Perrigo is a world leading health company which creates and provides non-prescription (ОТС) and perscription (Rx) medicines, consumer goods, food products and active pharmaceutical ingredients (API). Since 1887, Perrigo has been providing its customers and consumers with high-quality products that support personal health and wellness by delivering effective solutions that meet the needs of consumers almost all over the world – mostly in Northern America, Europe, Australia, and other key markets like Israel and China».
“the MAP of hope” – program to SUPPORT patients in areas such as Oncology.
Drugs project:
Ось переклад англійською мовою:
Tagrisso film-coated tablets 80 mg No. 30 (10×3)
Lynparza film-coated tablets 100 mg No. 56
Lynparza film-coated tablets 150 mg No. 56
Calquence hard capsules 100 mg No. 60
Calquence film-coated tablets 100 mg No. 60
More details about conditions of participation in the project can be found on https://kartanadii.com.ua/az_onko/
the Company RECORDED GROUPS, with headquarters in Milan (Italy), has offices in many countries of Central and Eastern Europe, in Russia, in Turkey, in North Africa and in the United States of America.
